Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Significant Segment Expenses

Significant segment expenses, as provided to the CODM are as follows:

	2024			2023
Sales	$	1,629,108			1,071,970
Cost of sales (excluding depreciation expense)		544,903			380,069
Research and development expense		2,217,610			2,051,902
Other research and development expenses1		5,998,933			5,156,799
Total research and development expense		8,216,543			7,208,701
Sales and marketing expense		4,030,150			650,126
General and administrative expense		6,325,999			6,858,008
Depreciation and amortization expense		297,318			483,481
Total Operating expenses		18,870,010			15,200,316
Total other (expense) income		(1,021,221	)		265,629
Loss before income taxes		(18,807,026	)		(14,242,786	)
Income tax expense		9,602			4,338
Net loss	$	(18,816,628	)		(14,247,124	)

¹ Other research and development expenses include clinical affairs, regulatory, manufacturing and quality assurance expenses.